1. Home
  2. SSM vs BOLT Comparison

SSM vs BOLT Comparison

Compare SSM & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sono Group N.V. Ordinary Shares

SSM

Sono Group N.V. Ordinary Shares

HOLD

Current Price

$2.55

Market Cap

6.4M

Sector

N/A

ML Signal

HOLD

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

HOLD

Current Price

$3.47

Market Cap

7.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSM
BOLT
Founded
2016
2015
Country
Germany
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
7.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
SSM
BOLT
Price
$2.55
$3.47
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$34.00
AVG Volume (30 Days)
25.6K
22.0K
Earning Date
05-20-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,695,000.00
Revenue This Year
$1,462,987.20
N/A
Revenue Next Year
$48.49
$133.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.07
52 Week Low
$2.35
$3.13
52 Week High
$10.54
$7.20

Technical Indicators

Market Signals
Indicator
SSM
BOLT
Relative Strength Index (RSI) 29.42 43.28
Support Level N/A $3.13
Resistance Level $4.43 $4.35
Average True Range (ATR) 0.28 0.26
MACD -0.04 -0.03
Stochastic Oscillator 20.34 33.58

Price Performance

Historical Comparison
SSM
BOLT

About SSM Sono Group N.V. Ordinary Shares

Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and services include Complete Solar Solutions, Solar Charge Controllers, Solar Modules, Data Services, and Engineering Services. The company's single business segment manages the financing, research and development, and product commercialization.

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

Share on Social Networks: